Form 4: C4 Therapeutics Director Donna Roy Grogan Acquires Stock Options
SEC Form 4 Filing
Director Donna Roy Grogan acquired 32,500 stock options in C4 Therapeutics, Inc. on June 20, 2024.
Summary
- On June 20, 2024, Donna Roy Grogan, a director of C4 Therapeutics, Inc. (CCCC), acquired 32,500 stock options.
- The options have an exercise price of $4.05.
- The options vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the Board.
- Following the transaction, Grogan directly owns 32,500 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon continued service, aligning the director's interests with the company's long-term success.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's increased stake in the company, which can be viewed positively by investors.
Stakeholder Impact
- Shareholders may view the director's increased stake as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Director Donna Roy Grogan acquired stock options. |
| 06/20/2025 | Earliest date for full vesting of the stock options. |
| 06/19/2034 | Expiration date of the stock options. |
| 06/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.